First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Tumor, Solid

In brief

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.

Key facts

Study ID

NCT04528836

Run by

Navire Pharma Inc., a BridgeBio company

People needed

72

Starts

2020-11-12

Expected to finish

2024-07-30

Last updated by the study team

2024-12-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• City of Hope — Duarte, California, United States
• Scripps MD Anderson Cancer Center — La Jolla, California, United States
• UC Irvine Health — Orange, California, United States
• UCLA Hematology/Oncology - Santa Monica — Santa Monica, California, United States
• Sarah Cannon Research Institute — Denver, Colorado, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States
• NEXT Virginia — Fairfax, Virginia, United States
• MultiCare Institute for Research & Innovation — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.